Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus by Marasini, Nirmal et al.
Accepted Manuscript
Title: Lipid core peptide/poly(lactic-co-glycolic acid) as a
highly potent intranasal vaccine delivery system against
Group A streptococcus
Author: Nirmal Marasini Zeinab G. Khalil Ashwini Kumar
Giddam Khairunnisa Abdul Ghaffar Waleed M. Hussein
Robert J. Capon Michael R. Batzloff Michael F. Good
Mariusz Skwarczynski Istvan Toth
PII: S0378-5173(16)30887-0
DOI: http://dx.doi.org/doi:10.1016/j.ijpharm.2016.09.057
Reference: IJP 16099
To appear in: International Journal of Pharmaceutics
Received date: 1-6-2016
Revised date: 15-9-2016
Accepted date: 19-9-2016
Please cite this article as: Marasini, Nirmal, Khalil, Zeinab G., Giddam, Ashwini
Kumar, Ghaffar, Khairunnisa Abdul, Hussein, Waleed M., Capon, Robert J.,
Batzloff, Michael R., Good, Michael F., Skwarczynski, Mariusz, Toth, Istvan,
Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine
delivery system against Group A streptococcus.International Journal of Pharmaceutics
http://dx.doi.org/10.1016/j.ijpharm.2016.09.057
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal 
vaccine delivery system against Group A streptococcus 
 
Nirmal Marasini a, Zeinab G. Khalil b, Ashwini Kumar Giddam a, Khairunnisa Abdul Ghaffar 
a, Waleed M. Hussein a, Robert J. Capon b, Michael R. Batzloff c, Michael F. Good c, Mariusz 
Skwarczynski a, Istvan Toth a, b, d* 
a The University of Queensland, School of Chemistry & Molecular Biosciences, St Lucia, 
QLD, 4072, Australia 
b The University of Queensland, Institute for Molecular Biosciences, St Lucia, QLD, 4072, 
Australia  
c Griffith University, Institute for Glycomics, Gold Coast, QLD, 4222, Australia 
d The University of Queensland, School of Pharmacy, Woolloongabba, QLD, 4102, Australia 
 
*Corresponding author      
Professor Istvan Toth      
School of Chemistry and Molecular Biosciences, 
The University of Queensland, 
St Lucia, QLD 4072, Australia. 
Tel.: +61 7 3346 9892 
Fax: +61 7 3365 4273 
Email: i.toth@uq.edu.au 
  
 
 
 
 
 
 
2 
 
 
Graphical abstract 
Lipid core peptide 
vaccine
Lipid core peptide 
vaccine
IgA 
antibodies
IgA 
antibodies
Intranasal 
immunization
Intranasal 
immunization
Lipid core peptide-encapsulated nanoparticle
Lipid core peptide-coated nanoparticle
IgG 
antibodies
IgG 
antibodies
 
Abstract 
 
Rheumatic heart disease represents a leading cause of mortality caused by Group A 
Streptococcus (GAS) infections transmitted through the respiratory route. Although GAS 
infections can be treated with antibiotics these are often inadequate. An efficacious GAS 
vaccine holds more promise, with intranasal vaccination especially attractive, as it mimics the 
natural route of infections and should be able to induce mucosal IgA and systemic IgG 
immunity. Nanoparticles were prepared by either encapsulating or coating lipopeptide-based 
vaccine candidate (LCP-1) on the surface of poly(lactic-co-glycolic acid) (PLGA). In vitro 
study showed that encapsulation of LCP-1 vaccine into nanoparticles improved uptake and 
maturations of antigen-presenting cells. The immunogenicity of lipopeptide incorporated 
PLGA-based nanoparticles was compared with peptides co-administered with mucosal 
adjuvant cholera toxin B in mice upon intranasal administration. Higher levels of J14-specific 
salivary mucosal IgA and systemic antibody IgG titres were observed for groups immunized 
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with encapsulated LCP-1 compared to LCP-1 coated nanoparticles or free LCP-1. Systemic 
antibodies obtained from LCP-1 encapsulated PLGA NPs inhibited the growth of bacteria in 
six different GAS strains. Our results show that PLGA-based lipopeptide delivery is a 
promising approach for rational design of a simple, effective and patient friendly intranasal 
GAS vaccine resulting in mucosal IgA response. 
 
Keywords: nanoparticles; lipopeptides; PLGA; vaccine; mucosal immunology 
 
 
1. Introduction 
The primary goal of any vaccine is to induce long lasting antigen-specific immunity 
against the pathogens. Most pathogens invade the human body through the mucosal route. 
Therefore, the development of mucosal vaccines that are able to produce neutralizing 
antibodies to prevent pathogen colonization at the primary site of contact (mucosal tissue) is 
desirable (Marasini et al., 2014). Parenterally administered vaccines normally induce 
systemic immunity, whereas mucosally administered vaccines should be able to 
simultaneously stimulate both mucosal and systemic immune responses (Lycke, 2012). 
Parenteral vaccines using whole pathogen-based live attenuated, or killed microorganisms as 
antigens, are usually highly immunogenic but not necessarily completely safe. Subunit 
vaccines, owing to their well-defined components, are expected to cause minimal side effects 
and toxicity. However, antigens in subunit-based vaccines are usually poorly immunogenic 
and the use of adjuvants is required for vaccine efficacy (Skwarczynski and Toth, 2016). 
Furthermore, the immunogenicity is lower for peptide antigens delivered through the mucosal 
route, even when administered with adjuvant, in comparison to the standard parental 
immunization (Csaba et al., 2009). Cholera toxin subunit B (CTB) is the most widely used 
mucosal adjuvant in experimental animals; however, CTB is potentially toxic and restricted 
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for animal use only. Therefore, the development of safe and efficacious mucosal adjuvants 
that are able to boost mucosal responses (IgA) is important for future clinical use.  
Group A streptococcus (GAS) causes several complications such as pharyngitis, 
impetigo, scarlet fever, acute rheumatic fever, rheumatic heart diseases and post-
streptococcal glomerulonephritis. In 2005, it was estimated  that at least 18.1 million people 
suffered from serious GAS diseases, with 1.78 million new cases every year, causing half a 
million deaths each year (Carapetis et al., 2005). To reduce the global health burden of GAS-
related diseases, an effective prevention approach is required. With the exceptions of 
healthier life-styles and easy access to health-care facilities, the development of safe, 
effective, and affordable vaccines is much warranted to prevent GAS-related post infection 
complications. GAS is often transmitted to the body from the throat, and primarily colonizes 
the mucosal tissue before systemic invasion in the blood. Induction of local immunity at the 
site of contact (nasopharyngeal tract) can be used as the first line of protection against GAS 
(Good et al., 2013). Thus, the nasal route is the preferred choice for vaccine administration 
against GAS. Lipopeptide vaccine candidate (LCP-1) incorporating minimal B-cell epitope 
derived from GAS M-protein called J14 and universal T-helper cell epitope (P25) was 
previously shown to be effective in the induction of humoral immune responses against GAS, 
upon systemic and intranasal administration (Fig. 1) (Abdel-Aal et al., 2008; Zaman et al., 
2012). Here, we propose a nanoparticle delivery system based on PLGA to further improve 
immunogenicity of LCP-1 while reducing the antigen dose.  
Nanoparticles (NPs) have shown huge potential as peptide/protein-based antigen 
carriers (Csaba et al., 2009; Skwarczynski and Toth, 2014). NPs protect the encapsulated 
antigens, improve their uptake by APCs, prolong interactions with antigen-presenting cells 
(APCs) and provide an additional danger signal to produce antigen-specific immune 
responses (Irvine et al., 2015). Poly (lactic-co-glycolic) acid (PLGA) is one of the more 
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extensively used polymers in antigen delivery systems. PLGA is non-toxic, non-
immunogenic, biodegradable and licensed for human use by the United States Food and Drug 
Administration (Danhier et al., 2012). While the interactions of NPs and APCs are important 
for vaccine efficacy, the location of antigens in the NPs could play a crucial role in the 
continual recruitment of APCs as well as determining the intensity or durability and quality 
of immune responses. Antigens are usually encapsulated, or adsorbed on the surface of 
PLGA NPs (Gregory et al., 2013). Incorporation of antigens in/on PLGA NPs is mainly 
facilitated by hydrophobic or electrostatic interactions. Recently, Liu et al. reported that 
antigen-encapsulated or antigen-both encapsulated and absorbed to the surface were better in 
eliciting antigen-specific immune responses compared with surface-adsorbed or free antigens 
(Liu et al., 2016). However, some studies have reported contradictory findings where surface-
attached antigens, or adsorbed onto NPs, were shown to have better immunogenicity than 
antigens encapsulated into NPs (Barnier-Quer et al., 2013; Briones et al., 2001; O'Hagan et 
al., 2001). Those studies were based only upon parenteral immunizations, therefore, the 
current study compared delivery systems prepared either by encapsulation or surface-
adsorption of lipopeptide vaccines onto PLGA NPs for their ability to induce mucosal 
immune responses upon intranasal administration in mice model.   
Lipid core peptide vaccine candidate (LCP-1, Fig.1) encapsulated in PLGA NPs 
(NPs-1) or LCP-1-coated PLGA NPs (NPs-2) were prepared (Fig. 2). Antigen-presenting 
cells (APCs) uptake of NPs and subsequent APCs’ maturation were accessed. PLGA NPs 
efficacy in mice was compared to free LCP-1, and a mixture of peptides bearing the same 
antigens as LCP-1 with or without cholera toxin B (CTB). The antibodies obtained from 
blood were assayed for their capacity to inhibit growth of several strains of GAS bacteria.  
2. Material and methods  
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2.1 Materials  
 Poly-(lactic-coglycolic-acid) (PLGA) (L: G, 50:50) (Mw: 10,000-15000) was 
purchased from PolySciTech® (United States). Dichloromethane (DCM), poly (vinyl 
alcohol) (PVA) (Mw: 30,000-70,000), phenylmethylsulfonylfluoride (PMSF), soybean 
trypsin inhibitor, 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate and all other reagents were 
purchased at the available purity from Sigma–Aldrich (Castle Hill, NSW, Australia). 
Antibodies, CD11c-A660, F4/80-APC-Cy7 and FITC-CD80 were purchased from BioLegend 
(CA, United States).  Secondary antibodies (IgG, IgG1, IgG2a and IgA) conjugated to 
horseradish peroxidase and CTB were purchased from sigma Aldrich (Australia).. 
Lysotracker® RedDND-99 was purchased from Life technologies (Victoria, Australia). All 
chemicals were used as received without any purification. For the opsonization assay, yeast 
extract was purchased from Merck, Todd-Hewitt broth from Oxoid, and horse blood from 
Serum Australia. Millipore water was used in all formulations or where required.  Lipid core 
peptide vaccine candidate (LCP-1) incorporating C-16 alkyl lipids (2-amino-D,L-
hexadecanoic acid) chemically conjugated by linker (Serine-Serine-Lysine) to B-cell epitope 
(J14, KQAEDKVKASREAKKQVEKALEQLEDKVK) and universal T-helper cell epitope 
(P25; KLIPNASLIENCTKAEL) were synthesized using microwave-assisted solid phase 
peptide synthesis (SPSS) method using Boc chemistry (Marasini et al., 2016; Skwarczynski 
and Toth, 2011). Further, peptides J14 and P25 were synthesized by SPSS using Fmoc 
chemistry (Ahmad Fuaad et al., 2016).  
2.2 Nanoparticle preparation  
A cationic amphiphilic vaccine candidate (LCP-1) (Fig. 1) and peptides J14 and P25 
were synthesized and purified as described previously (Marasini et al., 2016). LCP-1 was 
encapsulated into PLGA using the double emulsion solvent evaporation method (NPs-1). 
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Double emulsion method is widely used to encapsulate drugs and antigens (Pavot et al, 
2014). Briefly, LCP-1 (1.5 mg) was added to Millipore water (1 mL). PLGA (7.5 mg) was 
added to DCM (3 mL). To the organic solution, aqueous LCP-1 solution was slowly added to 
the DCM solution under stirring, and the mixture was sonicated (Branson sonifier 250, 
duration 2 min, duty cycle 50, output 4) to form a primary water-in-oil emulsion. Primary 
emulsion was added dropwise to 6.75 mL of 0.75% PVA solution forming a double emulsion 
(water-oil-water), then sonicated (Branson sonifier 250, duration 2 min, duty cycle 50, output 
4) and stirred overnight under atmospheric pressure to remove organic solvent (DCM).  NPs-
1 suspensions were centrifuged at 3,000 ×g for 3 min to remove large particles. Supernatant 
was transferred, and centrifuged at 15,000 ×g for 10 min to collect small-size particles. The 
small-sized particles were further washed with Millipore water and centrifuged (15,000 × g 
for 10 min) twice to remove non-entrapped LCP-1.  
LCP-1-coated PLGA NPs (NPs-2) were prepared by the single-emulsion solvent 
evaporation method where empty anionic PLGA nanoparticles were initially produced 
following subsequent coating with cationic LCP-1. The change in surface-charge was 
considered as evidence for successful surface coating of particles. Briefly, PLGA (7.5 mg) in 
DCM (3 mL) was added dropwise to 6.75 mL of 0.75% PVA. Upon evaporating the DCM, 
LCP-1 was added to the PVA solution and stirred for 2 h at room temperature. NPs were 
collected using a similar process to that described above. Unadsorbed LCP-1 was removed 
after twice washing with water. Particle size and zeta potential analysis were used to monitor 
formation of both NPs.  
 
2.3 Physicochemical characterizations 
2.3.1 Particle size distribution and zeta potentials 
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The average particle size, polydispersity index (PDI) and zeta potentials of the 
nanoparticles were determined using dynamic light scattering (DLS) at a back scattering 
angle of 173 °C using a Zetasizer ( Zetasizer Nano Series ZS, Malvern Instruments, United 
Kingdom). The results are expressed as an average of at least three measurements for each 
batch.  
2.3.2 Morphology 
Transmission electron microscopy (TEM, JEOL Ltd, Japan) was used to visualize the 
surface morphology of the nanoparticles. A drop of the sample was placed in a glow-
discharged carbon-coated grid and particles were allowed to settle in the grid for 2 min. The 
excess liquid was wicked off with filter paper and particles were stained with 1% 
phosphotungstic acid (pH, 7) for 30 sec. The excess stain solution was wicked away and the 
grid was air-dried for 5 min before taking the microscopic image. 
2.3.3 Loading efficiency and nanoparticle yield 
The quantities of LCP-1 encapsulated or surface-adsorbed onto PLGA NPs were 
measured by comparing with the known concentration of LCP-1 obtained from the standard 
calibration curve. In brief, particles were centrifuged at 15,000 × g for 20 min. Upon 
formation of pellets, the supernatant was removed, filtered (0.45 µm membrane filter) and 
measured for the content of free LCP-1 in the solution by employing reverse phase high 
performance liquid chromatography (RP-HPLC) using Shimadzu (Kyoto, Japan) 
instrumentation (DGU-20A5, LC-20AB, SIL-20ACHT, SPD-M10AVP). The flow rate was 
maintained at 1 mL min-1 , UV detection at wavelength 214 nm and/or evaporative light 
scattering detector (ELSD) using Vydac analytical C4 column (214TP54; 5 mm, 4.6 mm   
250 mm). The mobile phase comprising solvent A [0.1% trifluroacetic acid (TFA) in water] 
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and solvent B (0.1% TFA, v/v, in 90% acetonitrile) in a linear gradient from 40% A in B to 
100% B over 60 min.  
Loading efficiency was calculated as the percentage of the amount of LCP-1 in the 
NPs divided by the total weight of NPs. Entrapment efficiency percentage was obtained upon 
dividing total amount of LCP-1 in NPs by the total amount of LCP-1 fed initially. The 
formulations were centrifuged, sediment was freeze-dried and the yield was calculated as the 
percentage of amount of NPs divided by the total amount of polymers and LCP-1 fed 
initially. 
2.4 Antigen-presenting cells uptake and maturation studies  
Single cell suspensions of spleens were physically disrupted and passed through 
stainless-steel mesh. Erythrocytes were lysed using red blood cell lysis buffer (Sigma 
Aldrich, Australia). Cells were plated with 2 x 105 cells / well on a 96-well plate in phenol-
free IMDM Glutamax medium (Gibco®, Life science, CA. USA) supplemented with 10% 
fetal bovine serum, 50 μM 2-mercaptoethanol, 100 U/mL penicillin and 100 μg/mL 
streptomycin. NPs equivalent to 2 µg carboxyfluroscein-conjugated LCP-1 alone or 
encapsulated (NPs-1) or surface-coated onto PLGA NPs (NPs-2) were added to the each well 
and incubated at 37 °C for 6 h. Cells that adhered to wells were scraped and added to Fc-
block (eBioscience ,CA, USA) and incubated for 30 min at 4°C. The cells were centrifuged 
and resuspended in a buffer containing CD11c (eBioscience CA, USA) F4/80 (BioLegend, 
CA, USA), CD80 (BioLegend, CA, USA) and CD86 (eBioscience CA, USA) antibodies for 
30 min at 4 °C. The cells were then centrifuged, washed and resuspended in 0.5 ml of FACS 
buffer (PBS, 0.02% sodium azide, 0.5% BSA) using an LSR II flowcytometer (BD 
Biosciences). The mean fluorescence intensity positive between carboxyfluroscein-LCP-1 
and CD11C or F4/80 was used to quantify uptake by dendritic cells and macrophages, 
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respectively. Additionally, percentage fluorescence positive for CD11C or F4/80 cells and 
activation markers CD80 and CD86 were used to identify the maturation of dendritic cells or 
macrophages.    
2.5 Confocal imaging  
Complete splenocytes were incubated for 6 h at 37 °C, with carboxyfluroscein-tagged 
LCP-1 encapsulated NPs. Cells were extensively washed and fixed with a 4% w/v 
paraformaldehyde solution. Lysotracker® 100 µL (100 nM) was used to stain lysosomes. 
Stained cells were visualized under confocal microscopy (LSM710, Zeiss Co. Germany).    
2.6 Immunization study 
All studies were conducted in accordance with the National Health and Medical 
Research Council (NHMRC) of Australia guidelines and approved by the Institute of Ethics 
Review Board for animal-based work (Griffith University, GU ref no. Gly-01-15 AEC).  All 
animals (6 weeks age) were maintained under pathogen-free conditions with free access to 
food and water. Female outbred ARC-Swiss mice were obtained from the animal resource 
centre, Perth, Western Australia. Mice were divided into 6 different cohorts with 5 mice in 
each group. Immunizations were performed as follow; mouse was held in supine position 
with head tilted down and a formulation was administered slowly using micropipette to avoid 
nostril blockage. Each mouse received 10 µg LCP-1 alone or NPs bearing 10 µg LCP-1 at a 
volume of 10 µL (5 µL/nostril). Positive control groups received a mixture of peptides 
incorporating B cell epitope, J14 (20 µg) and universal T-helper cells epitope, P25 (20 µg) 
adjuvanted with CTB (10 µg). Additionally, another control group received similar 
formulations but without CTB. The negative control group received PBS at a total volume of 
10 µL (5 µL/nostril) for each mouse. Mice were immunized three times at 2-week intervals 
(Day 1, 14 and 28).     
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2.6.1 Sample collections 
 Blood samples were collected from a tail artery bleed on day 28 and 42. Sera was 
separated after centrifuging at 10,000 × g for 10 min. Saliva samples were collected upon 
intraperitoneal injection of pilocarpine solution (50 µL). Saliva was collected in a tube pre-
filled with 1 µL of protease inhibitor [100 mM phenylmethylsulfonylfluoride (PMSF)]. Both 
sera and salivary samples were stored immediately at -80 °C until further analysis.    
2.6.2 ELISA 
The sera and saliva from the immunized mice were tested for the presence of 
antibodies (IgG, IgG1, IgG2a and IgA) by the ELISA method as described earlier (Ghaffar et 
al., 2016). Briefly, microtitre plates (96-well) were coated with 50 µg of J14 antigen per plate 
prepared in carbonate-coating buffer (pH 9.6) followed by incubation at 37 °C for 90 min. 
The plates were washed with PBS-tween (PBST) (0.05%) mixture and then blocked with 5% 
skim milk in PBST solution overnight at 4 °C. The plates were washed, the sample added and 
two-fold serial dilution at a starting dilution of 1:200 (for serum IgG), 1:100 (serum IgG 
subtypes) and 1:4 (salivary IgA) for the sample for each mouse was performed. The plates 
were incubated at 37 °C for 90 min and then washed with PBST. Secondary antibodies (IgG, 
IgG1, IgG2a and IgA) conjugated to horseradishperoxidase were added to the plates and 
incubated at 37 °C for 90 min. Plates were washed, and combined with TMB substrate and 
then further incubated at room temperature for 20 min for colour development. The reactions 
were stopped using 2M H2SO4 and the absorbance was measured at 450 nm using a 
microplate reader (Spectramax, United States). Results were expressed as the end-point 
dilution that gave an absorbance of three standard deviations above the mean absorbance of 
control wells (sera/saliva from naïve unimmunized mice). The levels of antibody titres are 
expressed in log10 and log2 scale to represent IgG/IgG1/IgG2a and IgA, respectively.   
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2.7 Indirect bactericidal assay 
Mouse anti-J14 peptide sera samples were analysed for their ability to opsonize GAS 
in an indirect bactericidal assay as previously described with slight modification (Brandt et 
al., 2000). Different hospital strains of GAS (Streptococcus pyogens) were tested (Table 1). 
The bacterium to be tested was streaked on a Todd-Hewitt broth (THB) supplemented with 
5% yeast extract agar plate, and incubated at 37 °C for 24 h. A single colony was transferred 
to fresh THB (5 mL) supplemented with 5% yeast extract and grown overnight at 37 °C to 
give approximately 4.6 x 106 colony forming units (CFU) /mL. The culture was serially 
diluted to 10-2 in PBS from which an aliquot (10 µL) was mixed with fresh heat-inactivated 
sera (10 µL) and horse blood (80 µL). Inactivated sera were prepared by heating in a water 
bath at 50 °C for 30 min. Bacteria were grown in the presence of sera and incubated in a 96-
well plate at 37 °C for 3 h. To analyse bacterial survival, culture material (10 µL) was plated 
on Todd-Hewitt agar plates supplemented with 5% yeast extract and 5% horse blood. Plates 
were incubated at 37 °C for 24 h and colonies enumerated to CFU. Opsonic activity of the 
antibodies (anti-peptide) sera (% reduction in mean CFU) was calculated as [1-(CFU in the 
presence of anti-peptide sera)/ (mean CFU in the presence of PBS)] x 100. The assay was 
performed in triplicate from three independent cultures.  
2.8 Statistical analysis 
Statistical analysis was performed using one-way ANOVA and post-hoc Tukey test using 
GraphPad Prism (version 6). P values of <0.05(*), <0.01(**), <0.001(***) and 
<0.0001(****) were used to indicate statistical significance among the groups. 
3. Results  
3.1 Preparation and Characterizations of NPs 
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A cationic amphiphilic vaccine candidate (LCP-1) (Fig. 1) and peptides J14 and P25 
were synthesized in a high purity (>95%). NPs-1 were prepared using double-emulsion 
method, while NPs-2 were prepared by single-emulsion method followed by subsequent 
coating with LCP-1 (Fig.2). The amount of stabilizer (PVA) and the ratio of LCP-1 to PLGA 
were optimized-based on size and PDI measurements (Fig.S1 and S2). The NPs that were 
prepared at a ratio of LCP-1 to PLGA 1: 5 with PVA as a stabilizer at a concentration of 
0.75% showed the lowest particle size and PDI, and were selected for further study (Fig.S1 
and S2). The hydrophobic PLGA polymer formed particles entrapping LCP-1 inside the cores 
(NPs-1); however the presence of some LCP-1 molecules on the surface of the PLGA NPs 
could not be excluded (Fig. 2C). To prepare NPs-2, cationic LCP-1 was added to empty 
anionic PLGA NPs dispersions. LCP-1 was adsorbed on the surface of PLGA NPs via 
hydrophobic and electrostatic interactions between anionic PLGA and cationic LCP-1 (Fig. 
2D). We used a two-stage partial centrifugation technique to separate smaller particles from 
the larger particles. NPs suspended into PVA solutions were first subjected to low speed 
centrifugation at 3,000 × g for 3 min. Then, the large-sized particles were discarded and 
supernatants were subjected to a second-stage centrifugation at 15,000 × g for 10 min to 
isolate small particles. The free/unencapsulated/uncoated LCP-1 in NPs was removed upon 
twice washing with water. The mean particle size as measured by DLS showed 
monodispersed particles for empty NPs, LCP-1-encapsulated NPs (NPs-1) and LCP-1-coated 
NPs (NPs-2) with diameter approximately 205 nm, 198 nm, and 219 nm, respectively (Table 
2). Representative TEM images of NPs-1 and NPs-2 showed well-defined spherical-shaped 
particles with narrow-sized distributions and size-consistency to DLS measurements (Fig. 3). 
The zeta potentials observed for empty NPs, NPs-1 and NPs-2 were approximately -33 mV, 8 
mV and -4 mV, respectively (Table 2). The net negative charge of NPs-2 is attributed to their 
low entrapment efficiency of cationic LCP-1 on the surface of NPs as compared to NPs-1 
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(Table 2). The typical yield of particles upon the two-stage centrifugation technique was ~ 
6% (Table 2). Similar yields for the two-stage centrifugation method were previously 
reported (Zhou et al., 2013). DLS measurement obtained after re-dispersion of pellets 
following a single-stage centrifugation process (3,000 × g) showed highly polydispersed 
empty NPs, NPs-1 and NPs-2 with size approximately 470 nm, 750 nm and 521 nm, 
respectively. These larger particles were then discarded and never used (Table S1). 
Entrapment efficiencies of LCP-1 into NPs-1 and NPs-2 were approximately 71 % and 30 %, 
respectively, while the final loading capacities of LCP-1 in NPs-1 and NPs-2 were 
approximately 28% and 12 %, respectively (Table 2).   
 
3.2 Cellular uptake by antigen-presenting cells and subsequent maturation  
Splenocytes were harvested from naïve mice and stimulated with carboxyfluroscein-
conjugated LCP-1 bearing NPs. The treated DCs and macrophages were tagged with CD11c 
(the surface marker of DCs) and F4/80 (specific markers for murine macrophages) 
antibodies, respectively. Significantly higher numbers of APCs had taken up free LCP-1 or 
LCP-1 present in NPs-1 and NPs-2 compared to the group stimulated with PBS (Fig. 4 A and 
B). Among the studied groups, cationic LCP-1 showed the highest level of uptake by APCs. 
Although both NPs (NPs-1 vs NPs-2) possessed similar particle size, antigens encapsulated 
into the particles (NPs-1) were better taken up than antigens adsorbed on the surface of the 
particles (NPs-2) (Fig. 4A and B). The higher uptake of cationic NPs-1 (7.7 mV) compared to 
anionic NPs-2 (-4.5 mV) could be due to favourable interactions between the negatively 
charged membrane of APCs populations and positively-charged NPs-1 particles (Fig. 4A and 
B). However, it is important to note that the differences in antigen uptake by APC between 
the groups were not statistically significant. The efficiency of LCP-1 uptake by complete 
splenocytes population when encapsulated into NPs was further verified by fluorescence 
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microscopy images as indicated by the co-localized signal (yellow) between the green signal 
from carboxyfluroscein-LCP-1 and the red signal from endosomes (Fig. 4 C).   
Free LCP-1 did not induce significant maturations of APCs as indicated by low levels 
of maturation markers CD80 and CD86 (Fig. 5). The cationic LCP-1 encapsulated NPs (NPs-
1) which were readily taken up by APCs showed significantly higher upregulation of both 
maturations markers (CD80 and CD86) by APCs than free LCP-1 and PBS-treated groups 
(Fig. 5). The cationic NPs-1 expressed significantly higher levels of CD80+ markers in DCs 
and macrophages when compared to NPs-2 (Fig. 5 A and B).   
  
3.3 Mucosal immunization study 
To compare the influence of different NPs on antibody responses, mucosal 
immunization studies were conducted in Swiss out-bred mice. Each mouse was administered 
with either 10 µg free LCP-1 or 10 µg equivalents of LCP-1 (5 µL/nostril) encapsulated 
(NPs-1) or surface-coated NPs (NPs-2) by intranasal route every two weeks.  
After the second immunizations, mice administered with LCP-1 encapsulated NPs 
(NPs-1) showed a significant increase in J14-specific salivary IgA antibody titres compared 
to the PBS administered group (Fig. 6 A). Cationic NPs-1 showed significantly higher 
salivary antibody titres than LCP-1-coated NPs (NPs-2). Additionally, mice groups 
immunized with NPs-1 showed significantly higher J14-specific serum antibody titres as 
compared to the PBS administered group (Fig. 6 B). Although the NPs-1 group showed 
higher IgG titres than NPs-2, the difference was not statistically significant.   
Upon third immunizations, we observed significantly higher levels of salivary IgA 
antibody titres for LCP-1 encapsulated into NPs (NPs-1) compared with the PBS-
administered group (Fig. 6 C). The lead NPs-1 showed significantly higher antibody titres 
than groups immunized with free LCP-1, physical mixture of peptides adjuvanted with CTB, 
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and NPs-2. Mice immunized with LCP-1-coated on the surface of NPs (NPs-2) didn’t show 
significant improvement in salivary immune responses even after three immunizations 
despite the amount of antigen (LCP-1) being standardized (the same) for all tested delivery 
systems (Fig. 6 A and C). Physical mixtures of peptides adjuvanted with CTB upon three 
immunizations showed higher immune responses compared to two immunizations (Fig. 6 A 
and C). Mice administered with free LCP-1 or physical mixtures of peptides epitopes showed 
poor salivary IgA antibody production even after three immunizations (Fig. 6 C). Mice 
immunized with a physical mixture of peptides adjuvanted with CTB and NPs-1 showed 
significantly higher J14-specific serum antibody titres than mice immunized with PBS (Fig. 6 
D). In particular, mice immunized with NPs-2 showed significantly higher systemic IgG titres 
compared to free LCP-1 and NPs -1 (Fig. 6 D). In contrast, mice administered with NPs-2 
produced poor systemic IgG responses. The lead NPs-1 was accessed for its capacity to 
polarize either T-helper 1(Th1) or T-helper 2 (Th2) biased immune responses. Therefore, IgG 
isotypes [IgG1: directed by Th2 cells and IgG2a: directed by Th1 cells) antibodies were 
measured using serum obtained after three immunizations. NPs-1 showed mixed Th1/Th2 
responses and was mostly biased towards the Th2 polarized immune response (Fig. 7).   
 
3.4 Indirect bactericidal assay 
Antibodies produced upon immunization with NPs-1, and the positive and negative 
control groups were tested for their ability to opsonize different strains of GAS, including 
clinical isolates.  Both sera that were derived from  NPs-1 and CTB+J14+P25 groups showed 
significant levels of GAS opsonization when compared with sera derived from the mice 
group treated with PBS (Fig. 8). The average opsonic activity of sera in different GAS 
bacterial strains obtained from the NPs-1 group ranged from 24.3% to 95% while sera 
derived from peptides adjuvanted with the CTB group resulted in 46% to 78 % of 
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opsonization among tested GAS strains (Fig. 8). Importantly, NPs-1 group showed similar 
level of opsonic activity as positive control group (CTB+J14+P25).  
 
4. Discussion 
GAS-related diseases, particularly rheumatic fever and rheumatic heart disease remain 
a great public health burden especially in developing countries and in the indigenous 
communities of developed countries. An effective vaccine can prevent the occurrence of 
GAS-related post-infection complications; however, currently there is no vaccine available to 
combat these bacteria. GAS colonizes the nasopharyngeal mucosa before it invades the body 
systemically. Therefore an ideal vaccine is expected to produce mucosal antibodies (IgA) at 
the site of infection and systemic antibodies in the circulations (IgG) to clear infection. The 
conserved peptide-based epitopes (e.g., J14) derived from the most virulent GAS cell surface 
M-protein are promising antigens for GAS vaccine development. However, peptide epitopes 
are poorly immunogenic and require co-administration with adjuvants or a delivery system 
(Batzloff et al., 2005; Zaman et al., 2014). Lipopeptide incorporating two copies of 
lipoaminoacids (2- [R/S-tert-butoxycarbonyl)] amino hexadecanoic acid), GAS-derived B-
cell (J14) and universal T-helper cell (P25) epitopes is a promising vaccine candidate against 
GAS infection (LCP-1, Fig. 1) (Zaman et al., 2012). Upon intranasal immunization with 
LCP-1 at a dose of 60 µg per mouse, high levels of protective antigen-specific antibody titres 
were detected in mice models (Zaman et al., 2012; Zaman et al., 2014). The efficacy of this 
vaccine candidate was further improved upon by incorporation into liposomes (Ghaffar et al., 
2016). However, liposome possesses several limitations such as low stability due to vesicles 
merging, enzymatic digestions and premature leaking of antigens that compromise efficacy of 
nasally administered antigens (Ma et al., 2011). Therefore, a more stable and potent delivery 
systems is required. Recently, NPs have emerged as a successful platform for vaccine 
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delivery as they are biocompatible and able to improve the recognition and activation of 
antigens by immune systems (Irvine et al., 2015; Skwarczynski and Toth, 2014). Antigens 
can be encapsulated, adsorbed or conjugated to the surface of the NPs. While there is no 
doubt that formulations of antigens into NPs has the potential to enhance immune responses, 
the ideal antigen loadings methods could play a substantial role in determining the efficacy of 
antigen-specific immune responses. Therefore, immune responses after intranasal 
administration of lipopeptide vaccine into PLGA NPs as an antigen delivery vehicle were 
investigated by varying the antigen-loading method.  
An anionic PLGA polymer formulated as NPs can incorporate cationic LCP-1 vaccine 
candidate inside (NPs-1), or alternatively, LCP-1 can be adsorbed on the surface of NPs 
(NPs-2) (Fig. 2).This incorporation is mediated by electrostatic interactions and hydrophobic 
interactions between PLGA and LCP-1. Indeed, lipopeptides encapsulation efficacy, 
especially for NPs-1, was high in comparison with the typical encapsulation efficiency of 
non-lipidated peptides (Lutsiak et al., 2002). For comparison, we prepared both NPs with 
similar compositions, identical size and shape. Particle size plays a critical role in 
determining the potency of immune responses. Small-sized monodispersed PLGA NPs (~200 
nm) were better in crossing the nasal mucosal surface than micron-sized particles (1.5 µm) 
(Vila et al., 2005). Additionally, APCs preferentially take small particles and small particles 
can even travel to a draining lymph node without the help of peripheral APCs to induce 
stronger immune responses (Foged et al., 2005; Oyewumi et al., 2010; Skwarczynski and 
Toth, 2014). We used the two-stage partial centrifugation technique to ensure monodispersed 
small-sized nanoparticles were isolated to prepare a vaccine delivery system suitable for in 
vivo intranasal immunization study (Table 2) (Fig. 3).   
Dendritic cells (DCs) and macrophages are subsets of professional antigen presenting 
cells (APCs) which play a key role in the initiation and regulation of adaptive immune 
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responses. Upon encountering antigens, immature APCs differentiate into matured cells and 
present antigen to T-lymphocytes. This process is accompanied by the up-regulation of the 
co-stimulatory molecules such as CD80 and CD86 which is a benchmark for effective APCs’ 
maturation (Gong et al., 2015). Therefore, the uptake of NPs by APCs and their subsequent 
maturation capacity was accessed. Both PLGA-based NPs and free LCP-1 were highly taken 
up by APCs (Fig. 4). Interestingly, in spite of high uptake efficiency of free LCP-1 by APCs, 
LCP-1 alone was a poor inducer of APCs’ maturations (Fig. 5). A similar result was 
previously reported where even the high uptake (100%) of PLGA NPs encapsulating MART-
127-35 peptide was unable to improve DC maturations (Ma et al., 2011). Conversely, NPs-1 
showed enhanced uptake by APCs (DCs and macrophages) and higher expression of 
maturation markers than NPs-2 (Fig. 4 and 5). Improved maturation of APCs could be due to 
the prevention of peptide degradation, high LCP-1 entrapment efficiency, and prolonged 
antigen presentation to APCs (Pavot et al., 2014).  It was observed that APCs preferentially 
take up particles based on their surface-charge, and cationic-charged particles (Free LCP-1 
and NPs-1) are more favored by APCs than anionic particles (Fig. 4). Thus, uptake efficacy 
was charge-related while maturation of APCs was independent of the surface charge of NPs. 
Higher uptake by APCs doesn’t always guarantee initiation of immune responses (Slutter et 
al., 2009). After encountering antigens, only matured APCs activate T-lymphocyte 
proliferation to stimulate antibody responses. Our results showed that antigens encapsulated 
into polymeric particles with selective characteristics (e.g., cationic charge, nanosized 
particles) are beneficial for regulating the immune reaction cascade through the triggering of 
APCs’ maturation.  
An intranasal immunization study was performed in Swiss outbred mice. Simple 
physical mixtures of peptide epitopes (J14+P25) did not induce any humoral immune 
responses as expected (Fig. 6). Higher systemic and mucosal J14-specific antibody titres were 
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produced in the mice groups administered with NPs-1 compared with free LCP-1 or NPs-2 
(Fig. 6). Thus, antibody productions were mostly independent on the uptake efficacy of 
particles by APCs and dependent upon particles’ capacity to induce APCs’ maturation. Poor 
antibody responses of NPs-2 could be due to spontaneous shedding of lipopeptide antigens 
from the surfaces of PLGA NPs (Hanson et al., 2014). It can be assumed that NPs-1 released 
LCP-1 in APC’s endosomes while NPs-2 may release the antigen also before its uptake by 
APCs (Liu et al., 2015). The low immunogenicity of free LCP-1 was most likely related to 
the low dose of LCP-1 (10 µg/mouse) selected for this study. In contrast, much higher doses 
(e.g., 60 µg/mouse) were reported previously to achieve significant immune responses 
(Abdel-Aal et al., 2010; Zaman et al., 2012; Zaman et al., 2014). Additionally, NPs-1 was 
even more efficient or comparable to the positive control group (epitopes co-administered 
with CTB) in producing salivary IgA and serum IgG antibody titres (Fig. 6). These 
observations were in line with the results from APCs’ uptake and subsequent maturation 
experiments. Protections against GAS at systemic sites have been correlated with their ability 
to recognize and opsonize the bacteria. In vitro opsonic activities (bactericidal) of mice sera 
obtained from the NPs-1 group against different GAS strains showed significantly higher 
opsonizations up to 95% in clinical-isolates, as compared to PBS-treated groups (Fig. 8). In 
contrast, opsonization capacity in wild-type GAS strains from sera obtained after 
immunization with LCP-1 at a dose of 60 µg per mouse showed only a 33% reduction in 
CFU (Zaman et al., 2012).   
All of the above evidences indicated that intranasal administration of LCP-1 vaccine 
encapsulated into PLGA NPs could provide improved mucosal and systemic immune 
responses compared to free LCP-1 and surface-adsorbed LCP-1 PLGA NPs. It can be 
assumed that NPs-1 provided a slow or prolong exposure of LCP-1 by releasing LCP-1 in 
APCs endosomes while LCP-1 from NPs-2 might have released before their uptake by APCs 
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(Liu et al., 2015). Importantly, J14-specific mucosal and systemic antibody titres were shown 
to be related to protection capacity against GAS in vitro (Batzloff et al., 2005; Zaman et al., 
2012). 
  
5. Conclusion 
The rational use of PLGA-based NPs as a delivery platform for lipopeptide-based 
vaccines against GAS was demonstrated. Lipopeptide vaccines encapsulated within NPs 
elicited stronger antigen-specific systemic IgG and mucosal IgA immune responses than free 
lipopeptides or lipopeptides-coated NPs at a low dose (10 µg/mouse), signifying the 
importance of encapsulation of lipopeptide vaccines into the NPs. Additionally, the systemic 
antibodies produced in the mice group immunized with lipopeptides-encapsulated NPs were 
able to opsonize up to 95% of clinical strains of GAS. Improved immune response against 
GAS in the mice model was associated with the efficient uptake and subsequent maturation 
by APCs. Thus PLGA nanoparticles seem to be a very effective self-adjuvanting delivery 
platform for lipopeptide-based vaccines. 
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Figure 1. Chemical structure of lipid core peptide (LCP-1) vaccine candidate  
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Figure 2. Schematic representation of vaccine formulations: (A) LCP-1, (B) Empty PLGA 
nanoparticle (C) LCP-1 encapsulated nanoparticle, NPs-1 and (D) LCP-1-coated 
nanoparticle, NPs-2. 
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Figure 3. TEM images of nanoparticles: (A)  LCP-1 encapsulated nanoparticles, NPs-1 and 
(B) LCP-1-coated nanoparticles, NPs-2. 
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Figure 4.  Flow cytometry comparison of vaccine formulations uptake by CD11c+ dendritic 
cells (A) and F4/80+ macrophages (B) (n=3). Each bar represents the mean fluorescein 
intensity positive between carboxyfluroscein-LCP-1 and dendritic cell marker CD11c+ 
dendritic cells or F4/80+ macrophages. The differences between the groups were analysed 
using one-way ANOVA and post-hoc Tukey test. ns: p > 0.05; *p < 0.05; **p < 0.01; ***p < 
0.001; ****p < 0.001. (C) Representative images showing co-localization of fluorescein-
tagged LCP-1 with complete splenocytes at 63 × magnifications. The freshly isolated 
splenocytes were incubated with NPs-1 for 6 h at 37 °C, washed and fixed with 4% w/v 
paraformaldehyde solution before observing them in a fluorescent microscope. (i) LCP-1 
tagged with carboxyfluroscein (green colour) (ii) Lysotracker® (red colour) stained cell 
endosomes, (iii) bright field and (iv) merged images (green + red).   
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Figure 5. Flow cytometry comparison of expression of CD80 and CD86 maturation markers 
by mouse CD11c+ dendritic cells (A and C) and F4/80+ macrophages (B and D) upon 
stimulating with vaccine formulations. Cells were tagged with dendritic cells marker CD11c 
and macrophage marker F4/80. Bar represents the percentage of cells double positive for 
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CD11c or F4/80 and CD80 or CD86. The differences between the groups were analysed using 
one-way ANOVA and post-hoc Tukey test. ns: p > 0.05; *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.001.          
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Figure 6. J14-specific antibody titres after following intranasal immunization with different 
vaccine formulations in outbred Swiss mice, as analysed by ELISA. (A) J14-specific IgA 
antibody titres in saliva after 1st boosts (B) J14-specific IgG antibody titres in serum after 1st 
boosts. (C) J14-specific IgA antibody titres in saliva after 2nd boosts (D) J14-specific IgG 
antibody titres in serum after 2nd boosts. Each point in the figure represents an individual 
mouse (5 mice/group); the mean J14-specific titres are represented as a bar. Statistical 
analysis was performed using one-way ANOVA followed by the post-hoc Tukey test 
compared with PBS as indicated (ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001).  
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Figure 7.  J14-specific serum IgG isotype titres (log10) at 14th day after 2nd boosts upon 
intranasal immunization of Swiss mice. Error bar represents standard deviations (n=5).  
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Figure 8.  Average percentage opsonisation of different GAS strains by serum taken at day 
60 after 2nd boosts in Swiss mice (n=3).  Statistical analysis was performed using one-way 
ANOVA followed by the post-hoc Tukey test compared with PBS as indicated (ns, p > 0.05; 
*, p < 0.05; **, p < 0.01; ***, p < 0.001). 
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Table 1. List of various GAS strains used for bactericidal assay 
 
S.pyogenes strains Culture site 
ACM-2002 Royal Brisbane hospital, human abscess 
– lymph gland 
ACM-5199 = ATCC 12344, NCIB 
11841 
Scarlet fever 
ACM-5203 = ATCC 19615 Pharynx of child followed by episode of 
sore throat 
GC2 203 Wound swab 
D3840 Naso-pharynx swabs 
D2612 Naso-pharynx swabs 
 
 
 
 
 
 
 
 
 
 
 
 
  
39 
 
 
Table 2. Physicochemical characterizations of nanoparticles    
 
 
*LCP-1 vaccine candidate encapsulated into NPs  
**LCP-1 vaccine candidate surface-adsorbed onto NPs  
a
Entrapment efficiency (%): weight of LCP-1 in nanoparticles / weight of LCP-1 fed initially 
× 100 
b
Loading efficiency (%): weight of LCP-1 in nanoparticles /weight of nanoparticles × 100 
c
Nanoparticle yield calculated from supernatant obtained after 3,000 × g for 3 min followed 
by second centrifugation at 15,000 × g for 10 min followed by freeze-drying using following 
formula: Nanoparticle yield (%) = weight of nanoparticles/weight of polymers + LCP-1 fed 
initially × 100 
 
 
 
  
 
 
 
 
 Particle 
size (nm) 
PDI Charge 
(mV) 
Entrapment 
efficiency 
(%)a 
Loading 
efficiency 
(%)b 
Yield  
(%)c 
Empty NPs 205 ± 0.2 0.063 ± 0.03 -32.8 ± 0.5 - -  
NPs-1* 198 ± 1.2 0.248 ± 0.04 7.7 ± 2.6 71.4 ± 0.5 27.7 ± 0.2 5.7 
NPs-2** 219 ± 3.5 0.120 ±0. 03 -4.5 ± 0.2 29.5 ± 3.0 11.5 ± 1.2 6.3 
